Baseline demographics*
| Characteristic | CT-P13 5 mg/kg (N=125) | INX 5 mg/kg (N=125) | Total (N=250) |
|---|---|---|---|
| Age, years | 38.0 (18–69) | 38.0 (18–66) | 38.0 (18–69) |
| Gender, no. (%) | |||
| Male | 99 (79.2) | 103 (82.4) | 202 (80.8) |
| Female | 26 (20.8) | 22 (17.6) | 48 (19.2) |
| Ethnicity, no. (%) | |||
| Caucasian | 97 (77.6) | 92 (73.6) | 189 (75.6) |
| Asian | 16 (12.8) | 13 (10.4) | 29 (11.6) |
| Other | 12 (9.6) | 20 (16.0) | 32 (12.8) |
| Height, cm | 172.0 (148–198) | 171.0 (147–193) | 172.0 (147–198) |
| Weight, kg | 72.70 (45.0–120.0) | 76.00 (45.5–122.7) | 73.75 (45.0–122.7) |
| Body mass index, kg/m2 | 24.39 (18.0–38.7) | 25.64 (17.5–42.0) | 25.12 (17.5–42.0) |
| ASDAS, mean (SD) | 3.8 (0.8) | 3.9 (1.1) | 3.9 (1.0) |
| BASDAI (stratification factor), no. (%) | |||
| 4∼≤8 | 92 (73.6) | 95 (76.0) | 187 (74.8) |
| >8–10 | 33 (26.4) | 30 (24.0) | 63 (25.2) |
| BASDAI score, 0–10 | 6.8 (3.4–10.0) | 6.6 (1.8–10.0) | 6.7 (1.8–10.0) |
| BASFI score, 0–10 | 6.3 (0.7–9.8) | 6.3 (0.1–10.0) | 6.3 (0.1–10.0) |
| BASMI score, 0–10 | 4.0 (0.0–9.0) | 4.0 (0.0–9.0) | 4.0 (0.0–9.0) |
| Chest expansion, cm | 3.0 (0.5–9.0) | 2.5 (0.0–7.0) | 3.0 (0.0–9.0) |
| SF-36 summary scores | |||
| Physical component | 34.1 (16.2–49.7) | 33.1 (15.3–54.3) | 33.4 (15.3–54.3) |
| Mental component | 38.2 (15.1–63.7) | 37.2 (12.5–63.6) | 37.8 (12.5–63.7) |
| CRP level, mg/dl | 1.1 (0.0–13.0) | 1.4 (0.0–17.4) | 1.3 (0.0–17.4) |
| ESR level, mm/h | 33.0 (2.0–110.0) | 34.0 (1.0–119.0) | 34.0 (1.0–119.0) |
*Except where indicated otherwise, values are the median (minimum, maximum).
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; INX, innovator infliximab; SF-36, quality-of-life questionnaire (Medical Outcomes Study Short-Form Health Survey).